Preparations for DAVA Whistler Heme 2025 are underway! This meeting will bring together expert scientists and clinicians to discuss the current and future treatment landscape in hematologic malignancies. Register for the free virtual program-#Oncology

The 2024 DAVA Summit on Genitourinary Malignancies has come to a close. We extend our gratitude to all participants for their valuable insights, expertise, and engaging questions and answers. #DAVAGU

Dr. Matthew Dallos @MSKCancerCenter presents the NeoRED-P study, focusing on neoadjuvant immunotherapy in high-risk localized prostate cancer. Study will allow to understand the biology and test the feasibility of immunotherapy in the neoadjuvant setting. #DAVAGU

Dr. Russell Szmulewitz @UChicagoMed discusses Phase II trial on relacorilant, a glucocorticoid receptor antagonist, with enzalutamide and ADT for high-risk localized prostate cancer. The study aims to improve pathologic response rates. #DAVAGU

Dr. Scott Eggener @uroegg presents the Stockholm3 (STHLM3) test, a blood-based biomarker that improves prostate cancer screening by reducing unnecessary biopsies and detecting high-risk cancers. The test shows promising results across diverse racial and ethnic groups. #DAVAGU

Starting Now: Novel Therapies and Targets in Prostate Cancer Moderated by: @charlesryanmd #DAVAGU

Dr. Arnab Basu @arnabguonc from @ONealCancerUAB unveils the role of ultrasensitive ctDNA as a key prognostic tool in advanced #RCC, paving the way for more accurate monitoring and personalized treatment plans. #DAVAGU

Understanding the genetic drivers in #RCC: Dr. Mark Ball @markballmd discusses hLRCC and SDH/FDH-associated syndromes in RCC #DAVAGU

Exploring the impact of Birt-Hogg-Dubé syndrome and BAP1 mutations in #RCC and beyond: Dr. Maria Carlo from @sloan_kettering delves into the relevance of these genetic factors in cancer development and treatment. #DAVAGU

Starting Now: Translational Research in Renal Cell Carcinoma Syndromes Moderated by: Dr. Eric Jonasch @MDAndersonNews #DAVAGU

Unlocking the role of NK cells in #ProstateCancer: Dr. Nicholas Zorko from @UMNCancer explores the prognostic and predictive value of NK-cell infiltration, paving the way for new biomarkers and therapeutic strategies. #DAVAGU

#ProstateCancer treatment with CAR-T! Dr. David Oh @UCSFCancer explores ongoing trials, toxicity management, and the roadmap ahead. #DAVAGU

Advancing #RCC treatment with innovative cellular therapies! Dr. Paul Lin @pablolin highlights the promise of CD70-targeting NK cells. #DAVAGU

Starting Now: Cellular Therapy in RCC and Prostate Moderated by: @jackiebrown_MD #DAVAGU

Engaging talk by Dr. Scott Eggener @uroegg from @UChicago highlighting the importance of prostate cancer screening and active surveillance. While PSA screening saves lives, strategies to reduce over-detection and over-treatment are crucial. #DAVAGU

Excellent talk by @WalterStadler5 from @UChicagoMed on "There’s More to Length of Survival than Survival," exploring surrogate endpoints, novel survival analysis tools, and considerations for elderly patients in the era of extended survival in prostate cancer. #DAVAGU

Starting Now: Real-world Evidence and Clinical Trial Design in GU Malignancies Moderated by: Dr. Maria Carlo @MSKCancerCenter #DAVAGU

Does the polygenic risk score (PRS) predict prostate cancer risk? Dr. Kerry Schaffer @VUMChealth explains: PRS improves discrimination for any prostate cancer but not higher-grade disease. Future directions focus on combining PRS with other tools and refining outcomes. #DAVAGU

The Kidney Cancer Research Consortium (KCRC), presented by Eric Jonasch @MDAndersonNews, focuses on linking RCC subtypes to specific treatments via hypothesis-driven trials and predictive biomarkers, fostering tailored RCC research and collaboration. #DAVAGU

Dr. @charlesryanmd from @MSKCancerCenter presents on Prostate Cancer Clinical Trial Consortium (PCCTC), a global network focused on innovative clinical trials that translate scientific discoveries into improved standards of care. #DAVAGU